Table 3

Baseline and follow-up values (mean±SD) of individual variables and composite measures of 99 patients in the observational data set (average interval between visits: 2.8±3.5 months)

BaselineVisit 2Visit 3
Pain3.1±2.22.3±1.9**2.2±2.0
PtGA2.9±2.52.2±2.12.0±2.1
EGA2.0±2.01.2±1.4**0.9±1.0**
SJC281.3±2.31.0±1.90.6±1.1*
TJC282.2±4.01.8±3.61.3±2.7
SJC661.6±2.61.1±1.9*0.7±1.3*
TJC683.0±6.02.1±4.01.6±3.2
DAS28ESR2.7±1.52.6±1.42.5±1.1
DAS28CRP2.2±1.11.9±0.9*1.7±0.9*
SDAI10.6±10.97.7±8.6*5.3±6.1*
CDAI8.5±8.76.3±7.0*4.8±5.7*
DAREA12.9±13.08.8±9.2*7.2±7.6*
CRP (mg/dl)1.4±3.80.8±4.00.6±1.4
ESR15.3±16.217.6±16.015.9±10.7
HAQ0.5±0.60.4±0.60.4±0.6
  • * p<0.05,

  • ** p<0.01 for testing the follow-up compared to baseline values.

  • CDAI, clinical disease activity index; CRP, C reactive protein; DAREA, ‘Disease Activity index for REactive Arthritis’; DAS28, disease activity score using 28 joint counts; EGA, evaluator global assessment VAS (cm); ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; pain, patient pain VAS (cm); PtGA, patient global assessment VAS (cm); SDAI, simplified disease activity index; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.